These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11602551)

  • 1. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.
    Budts W; Van Pelt N; Gillyns H; Gewillig M; Van De Werf F; Janssens S
    Heart; 2001 Nov; 86(5):553-8. PubMed ID: 11602551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms.
    Rimensberger PC; Spahr-Schopfer I; Berner M; Jaeggi E; Kalangos A; Friedli B; Beghetti M
    Circulation; 2001 Jan; 103(4):544-8. PubMed ID: 11157720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
    Ziegler JW; Ivy DD; Wiggins JW; Kinsella JP; Clarke WR; Abman SH
    Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1388-95. PubMed ID: 9817684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.
    Michelakis E; Tymchak W; Lien D; Webster L; Hashimoto K; Archer S
    Circulation; 2002 May; 105(20):2398-403. PubMed ID: 12021227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial alterations during inhaled NO in lambs with pulmonary hypertension: implications for rebound hypertension.
    Ross GA; Oishi P; Azakie A; Fratz S; Fitzgerald RK; Johengen MJ; Harmon C; Hendricks-Munoz K; Xu J; Black SM; Fineman JR
    Am J Physiol Lung Cell Mol Physiol; 2005 Jan; 288(1):L27-35. PubMed ID: 15347565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
    Santini F; Casali G; Franchi G; Auriemma S; Lusini M; Barozzi L; Favaro A; Messina A; Mazzucco A
    Int J Cardiol; 2005 Aug; 103(2):156-63. PubMed ID: 16080974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery.
    Schmid ER; Bürki C; Engel MH; Schmidlin D; Tornic M; Seifert B
    Anesth Analg; 1999 Nov; 89(5):1108-15. PubMed ID: 10553820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension.
    Pearl JM; Nelson DP; Raake JL; Manning PB; Schwartz SM; Koons L; Shanley TP; Wong HR; Duffy JY
    Crit Care Med; 2002 Jan; 30(1):89-93. PubMed ID: 11902294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study.
    Hermon M; Golej J; Burda G; Marx M; Trittenwein G; Pollak A
    Artif Organs; 1999 Nov; 23(11):975-8. PubMed ID: 10564300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.
    Zwissler B; Kemming G; Merkel M; Wolfram G; Kleen M; Habler O; Haller M; Briegel J
    Eur J Med Res; 1999 Nov; 4(11):463-7. PubMed ID: 10585301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled nitric oxide in cardiac failure: vascular versus ventricular effects.
    Hayward CS; Rogers P; Keogh AM; Kelly R; Spratt PM; Macdonald PS
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):80-5. PubMed ID: 8656663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.
    Krasuski RA; Warner JJ; Wang A; Harrison JK; Tapson VF; Bashore TM
    J Am Coll Cardiol; 2000 Dec; 36(7):2204-11. PubMed ID: 11127462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension.
    Post MC; Janssens S; Van de Werf F; Budts W
    Eur Heart J; 2004 Sep; 25(18):1651-6. PubMed ID: 15351165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
    Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
    Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics.
    Matamis D; Pampori S; Papathanasiou A; Papakonstantinou P; Tsagourias M; Galiatsou E; Koulouras V; Nakos G
    Circ Heart Fail; 2012 Jan; 5(1):47-53. PubMed ID: 22057829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhalation nitric oxide during heart transplantation].
    Kozlov IA; Poptsov VN
    Anesteziol Reanimatol; 1999; (5):9-14. PubMed ID: 10560143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs.
    Thelitz S; Oishi P; Sanchez LS; Bekker JM; Ovadia B; Johengen MJ; Black SM; Fineman JR
    Pediatr Crit Care Med; 2004 May; 5(3):234-9. PubMed ID: 15115560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled nitric oxide in congenital heart disease.
    Roberts JD; Lang P; Bigatello LM; Vlahakes GJ; Zapol WM
    Circulation; 1993 Feb; 87(2):447-53. PubMed ID: 8425292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
    Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
    Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.